CA3117336A1 - Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1 - Google Patents

Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1 Download PDF

Info

Publication number
CA3117336A1
CA3117336A1 CA3117336A CA3117336A CA3117336A1 CA 3117336 A1 CA3117336 A1 CA 3117336A1 CA 3117336 A CA3117336 A CA 3117336A CA 3117336 A CA3117336 A CA 3117336A CA 3117336 A1 CA3117336 A1 CA 3117336A1
Authority
CA
Canada
Prior art keywords
compound
compound according
patient
xrpd
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3117336A
Other languages
English (en)
French (fr)
Inventor
Silvia LENZINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navitor Pharmaceuticals Inc
Original Assignee
Navitor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navitor Pharmaceuticals Inc filed Critical Navitor Pharmaceuticals Inc
Publication of CA3117336A1 publication Critical patent/CA3117336A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CA3117336A 2018-10-24 2019-10-24 Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1 Pending CA3117336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749922P 2018-10-24 2018-10-24
US62/749,922 2018-10-24
PCT/US2019/057815 WO2020086816A1 (en) 2018-10-24 2019-10-24 Polymorphic compounds and uses thereof

Publications (1)

Publication Number Publication Date
CA3117336A1 true CA3117336A1 (en) 2020-04-30

Family

ID=70328246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3117336A Pending CA3117336A1 (en) 2018-10-24 2019-10-24 Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1

Country Status (8)

Country Link
US (4) US11345654B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870158A4 (cg-RX-API-DMAC7.html)
JP (2) JP7644002B2 (cg-RX-API-DMAC7.html)
CN (1) CN113164414A (cg-RX-API-DMAC7.html)
AU (2) AU2019364542B2 (cg-RX-API-DMAC7.html)
CA (1) CA3117336A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021004710A (cg-RX-API-DMAC7.html)
WO (1) WO2020086816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
CN115927459A (zh) * 2022-07-19 2023-04-07 华南农业大学 猪ctns基因在促进动物骨骼肌生长中的应用
KR20250111125A (ko) * 2022-11-01 2025-07-22 나비토르 파마슈티칼스 인코포레이티드 mTORC1 활성의 조절제 및 이의 용도

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110368A (en) 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4346110A (en) 1981-06-01 1982-08-24 Merrell Toraude Et Compagnie Method for treating depression
JPS61149964A (ja) 1984-12-25 1986-07-08 Canon Inc 電子写真感光体
US4670196A (en) 1985-09-05 1987-06-02 Norton Company Tower packing element
ES2029799T3 (es) 1986-01-24 1992-10-01 Toray Industries, Inc. Derivados de 2,5,6,7 tetranor-4,8-inter-m-fenilen pg12.
GB8827885D0 (en) 1988-11-30 1989-01-05 Wellcome Found Novel heterocyclic pesticidal compounds
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
DE19623142A1 (de) 1996-06-10 1997-12-11 Huels Chemische Werke Ag Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung
HUP9903916A3 (en) 1996-08-28 2001-06-28 Procter And Gamble Co Cincinna Phosphinic acid amides and pharmaceutical compositions containing the same
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
WO1999055688A1 (en) 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
BR9907140A (pt) 1998-11-04 2000-10-17 Montell Technology Company Bv Componentes catalìticos sólidos, catalisadores e processo para a (co) polimerização de olefinas ch2=chr.
US6329546B1 (en) 1999-01-12 2001-12-11 Laboratory Of Molecular Biophotonics Caged amino acids
US20030203900A1 (en) 1999-05-18 2003-10-30 Martin Quibell Cysteine protease inhibitors
CZ300834B6 (cs) 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
US6787664B2 (en) 2002-09-17 2004-09-07 Warner-Lambert Company Llc Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US20070212428A1 (en) 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
MX2007009985A (es) 2005-02-18 2008-03-11 Innodia Inc Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos.
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
CN101573334A (zh) 2006-08-21 2009-11-04 普雷萨药品公司 用于治疗中枢神经系统障碍的多介质转运体抑制剂
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2069339B1 (en) 2006-09-25 2011-05-18 Wockhardt Research Centre Substituted piperidinophenyl oxazolidinones
TWI397418B (zh) 2006-10-10 2013-06-01 Otsuka Pharma Co Ltd 抗憂鬱劑
RU2009118935A (ru) 2006-10-20 2010-11-27 Мерк энд Ко., Инк. (US) Земещенные имидазолы в качестве модуляторов подтипа 3 бомбезиновых рецепторов
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
CA2786245A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
EP2678037B1 (en) 2011-02-25 2014-12-03 Lonza Ltd Branched linker for protein drug conjugates
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013142229A1 (en) 2012-03-19 2013-09-26 President And Fellows Of Harvard College Designing novel peptides for inducing fibronectin matrix assembly
EP3202397B1 (en) 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
US20160002159A1 (en) 2013-02-13 2016-01-07 Neal ZONDLO Perfluoro-tert-butyl hydroxyproline
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
WO2014201111A1 (en) * 2013-06-14 2014-12-18 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
EP3060231A1 (en) 2013-10-23 2016-08-31 The Whitehead Institute for Biomedical Research Mtorc1 modulation by amino acids and uses thereof
JP2018507910A (ja) 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
WO2017083823A1 (en) 2015-11-13 2017-05-18 Brandeis University Mtor inhibitors and methods of use thereof
US10512656B2 (en) * 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
JP6872768B2 (ja) 2016-10-21 2021-05-19 国立大学法人山口大学 mTORC1活性化抑制剤
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US10653652B2 (en) 2018-02-08 2020-05-19 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
US10926803B2 (en) 2019-07-17 2021-02-23 GM Global Technology Operations LLC Four rail front crush structure with load dissemination into eight element support structure
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator

Also Published As

Publication number Publication date
US20200131114A1 (en) 2020-04-30
EP3870158A4 (en) 2022-08-10
JP2025000975A (ja) 2025-01-07
US11345654B2 (en) 2022-05-31
US12252456B2 (en) 2025-03-18
JP7644002B2 (ja) 2025-03-11
US11697633B2 (en) 2023-07-11
EP3870158A1 (en) 2021-09-01
US20240018091A1 (en) 2024-01-18
CN113164414A (zh) 2021-07-23
US20220371985A1 (en) 2022-11-24
AU2019364542B2 (en) 2025-08-28
MX2021004710A (es) 2021-06-04
WO2020086816A1 (en) 2020-04-30
US20250188017A1 (en) 2025-06-12
MX2025010903A (es) 2025-10-01
AU2019364542A1 (en) 2021-06-10
AU2025271494A1 (en) 2026-01-08
JP2022505849A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
US12252456B2 (en) Polymorphic compounds and uses thereof
EP4556069A2 (en) Modulators of sestrin-gator2 interaction and uses thereof
JP6458168B2 (ja) グレリンo−アシルトランスフェラーゼ阻害剤
CN117050013A (zh) 6-氨基异喹啉的单(酸)盐及其用途
US20230202998A1 (en) Phenethylamine compounds salts, polymorphic forms and methods of use thereof
CN103917093B (zh) 视蛋白结合配体、组合物及使用方法
MX2011011756A (es) Sales de acido 3-pentilfenilacetico y usos farmaceuticos.
US11584741B2 (en) Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation
MX2011006791A (es) Compuestos de metodos para el tratamiento de dolor y otras enfermedades.
TW200927090A (en) Novel sulfamate compounds for medical use
CN102918050B (zh) 肠顶端膜钠/磷协同转运的芳基氟磷酸酯抑制剂
CN113557019A (zh) 取代的稠和咪唑衍生物和治疗镰状细胞病和相关并发症的方法
CN111939259A (zh) Na/K-ATP酶抑制剂及其应用
AU2023374029A1 (en) MODULATORS OF mTORC1 ACTIVITY AND USES THEREOF
US10399946B2 (en) Solid forms of an S-Nitrosoglutathione reductase inhibitor
CN112843041A (zh) 迷迭香酸或其衍生物作为新型trpc1拮抗剂的药用制备及其应用
TW202440535A (zh) 吡喃葡萄糖基衍生物的晶型及其用途
RU2569305C1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 2-ХЛОРО-4-МЕТОКСИ-N-[4-(8-МЕТИЛ-ИМИДАЗО[1,2-а]ПИРИДИН-2-ИЛ)-ФЕНИЛ]-БЕНЗАМИДА, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
CA3130396A1 (en) Isotopically-stabilized tetronimide compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220906

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240916

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241018

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250620

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250620

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260127

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20260424

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260424

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260424

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260428

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20260520

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260520

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20260618

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260618

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260618

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260618

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260618

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260618

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260713

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260714

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260729